Trials / Completed
CompletedNCT05469646
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1819479 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1819479 in healthy male Japanese subjects receiving single rising doses (SRD) in order to provide the basis for a clinical development of BI 1819479 in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1819479 | BI 1819479 |
| DRUG | Matching placebo | Matching placebo |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2022-12-20
- Completion
- 2022-12-27
- First posted
- 2022-07-22
- Last updated
- 2023-04-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05469646. Inclusion in this directory is not an endorsement.